Hawaii Awarded First Research Study on Lewy Body Dementia Investigating Remlifanserin (ACP-204)
The Hawaii Parkinson’s & Movement Center and Hawaii Parkinson’s Research Unit have been awarded Hawaiʻi’s first clinical research study focused on Lewy Body Dementia (LBD). This landmark study investigates ACP-204 (remlifanserin), an investigational medication developed to treat hallucinations and delusions associated with Lewy Body Dementia, a condition with significant unmet medical need . Understanding Lewy […]